Akston Launches Clinical Trial for Innovative Once-Weekly GLP-1 Weight Management Therapy for Cats Akston has initiated a clinical trial at Cornell University for a GLP-1 weight-management therapy aimed at helping overweight cats achieve better health through weekly dosing.

Akston Launches Clinical Trial for Innovative Once-Weekly GLP-1 Weight Management Therapy for Cats #None #GLP-1 #Cornell_University #Beverly,_Massachusetts #Akston

Akston launches clinical trial for novel canine cancer therapy | dvm360 The Akston Biosciences Corporation partnered with Purdue University to develop a drug targeting PD-L1 in dogs with solid tumors.

A clinical trial has been launched for a novel cancer drug for dogs. This injectable therapy targets PD-L1 in patients with solid tumors.

Read more: www.dvm360.com/view/akston-...

#PetCancer #Akston @pucvm.bsky.social
📷 Akston Biosciences

Akston Launches Innovative Cancer Therapy for Dogs in Clinical Trials Explore Akston's groundbreaking Ambifect® therapy for canine cancer, featuring a unique approach to immunotherapy and an inspiring first patient.

Akston Launches Innovative Cancer Therapy for Dogs in Clinical Trials #USA #West_Lafayette #Akston #Canine_Cancer #Ambifect

Akston Strengthens Leadership with New Veterinarians for Pet Biologics Development Akston enhances its leadership with the addition of two veterinarians, focusing on pioneering biologics for pets, including cancer therapies and chronic pain solutions.

Akston Strengthens Leadership with New Veterinarians for Pet Biologics Development #USA #Biologics #Beverly,_Massachusetts #Akston #Veterinarians